[HTML][HTML] Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized …
Background Immunotherapy agents are an innovative oncological treatment modality and as
a result their use has expanded widely. Understanding the treatment-related adverse events …
a result their use has expanded widely. Understanding the treatment-related adverse events …
A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up
D Kerrigan, CE Kennedy, R Morgan-Thomas… - The Lancet, 2015 - thelancet.com
A community empowerment-based response to HIV is a process by which sex workers take
collective ownership of programmes to achieve the most effective HIV outcomes and …
collective ownership of programmes to achieve the most effective HIV outcomes and …
The economic burden of racial, ethnic, and educational health inequities in the US
Importance Health inequities exist for racial and ethnic minorities and persons with lower
educational attainment due to differential exposure to economic, social, structural, and …
educational attainment due to differential exposure to economic, social, structural, and …
A health opportunity cost threshold for cost-effectiveness analysis in the United States
DJ Vanness, J Lomas, H Ahn - Annals of internal medicine, 2021 - acpjournals.org
Background: Cost-effectiveness analysis is an important tool for informing treatment
coverage and pricing decisions, yet no consensus exists about what threshold for the …
coverage and pricing decisions, yet no consensus exists about what threshold for the …
[PDF][PDF] Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
PJ Neumann, JT Cohen, MC Weinstein - N Engl J Med, 2014 - med.unipmn.it
797 ferred a threshold of $200,000 to $300,000 per QALY on the basis of increases in health
care spending over time and the health gains that have been associated with those …
care spending over time and the health gains that have been associated with those …
The case against education: Why the education system is a waste of time and money
B Caplan - 2019 - torrossa.com
When I started writing this book, I knew I'd need to read piles of research but failed to foresee
the enormity of the piles. Education isn't just a major industry; it inspires researchers' …
the enormity of the piles. Education isn't just a major industry; it inspires researchers' …
Short-term costs of preeclampsia to the United States health care system
Background Preeclampsia is a leading cause of maternal morbidity and mortality and
adverse neonatal outcomes. Little is known about the extent of the health and cost burden of …
adverse neonatal outcomes. Little is known about the extent of the health and cost burden of …
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo …
AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin… - The lancet …, 2009 - thelancet.com
Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
J Chhatwal, F Kanwal, MS Roberts… - Annals of internal …, 2015 - acpjournals.org
Background: Sofosbuvir and ledipasvir, which have recently been approved for treatment of
chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old …
chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old …
Delivering affordable cancer care in high-income countries
The burden of cancer is growing, and the disease is becoming a major economic
expenditure for all developed countries. In 2008, the worldwide cost of cancer due to …
expenditure for all developed countries. In 2008, the worldwide cost of cancer due to …